Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | Treatment combinations being explored with belantamab mafodotin in multiple myeloma

Malin Hultcrantz • 14 Jun 2022

EHA 2022

Multiple Myeloma Antibodies Belantamab mafodotin Bortezomib Carfilzomib Lenalidomide Nirogacestat Pomalidomide

DREAMM-14 DREAMM-5 DREAMM-6

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights some treatment combinations being explored with belantamab mafodotin and clinical trials investigating these regimens, including DREAMM-6 (NCT03544281), DREAMM-14 (NCT05064358), and DREAMM-5 (NCT04126200). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK

The role of immunotherapy in smoldering myeloma

Malin Hultcrantz • 10 Dec 2023

Should patients with smoldering myeloma be treated outside of the clinical trial setting?

Malin Hultcrantz • 10 Dec 2023

Serum biomarkers as predictors of disease progression in smoldering myeloma

Malin Hultcrantz • 10 Dec 2023

Real-world safety and efficacy of belantamab mafodotin in R/R myeloma

Malin Hultcrantz • 28 Sep 2023

Related Videos

Looking forward to the Miami Myeloma MRD Virtual Meeting 2024

Ola Landgren • 13 Apr 2024

The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma

Faith Davies • 9 Apr 2024

Upcoming studies investigating linvoseltamab in myeloma

Faith Davies • 9 Apr 2024

Molecular characteristics associated with increased risk of disease progression in SMM

Mark Bustoros • 27 Sep 2023